Morten Bagger

428 total citations
17 papers, 264 citations indexed

About

Morten Bagger is a scholar working on Oncology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Morten Bagger has authored 17 papers receiving a total of 264 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Immunology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Morten Bagger's work include Multiple Sclerosis Research Studies (4 papers), Peripheral Neuropathies and Disorders (3 papers) and Drug Transport and Resistance Mechanisms (3 papers). Morten Bagger is often cited by papers focused on Multiple Sclerosis Research Studies (4 papers), Peripheral Neuropathies and Disorders (3 papers) and Drug Transport and Resistance Mechanisms (3 papers). Morten Bagger collaborates with scholars based in Switzerland, United States and Denmark. Morten Bagger's co-authors include Erik Bechgaard, Bente Steffansen, Michael Christensen, Bernd C. Kieseier, Dieter A. Häring, Roman Willi, Ratnakar Pingili, Ayan Das Gupta, Prakash Krishnan and Ashley Vo and has published in prestigious journals such as Neurology, International Journal of Pharmaceutics and Structure.

In The Last Decade

Morten Bagger

17 papers receiving 257 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Morten Bagger Switzerland 9 73 67 58 55 51 17 264
Poorva Jain United States 9 11 0.2× 32 0.5× 103 1.8× 35 0.6× 19 0.4× 13 296
Alan I. Mandell United States 14 55 0.8× 49 0.7× 77 1.3× 11 0.2× 20 0.4× 22 598
Mahmoud Al‐Kofahi United States 11 27 0.4× 5 0.1× 70 1.2× 29 0.5× 62 1.2× 26 262
Sakae Itoga Japan 15 103 1.4× 5 0.1× 245 4.2× 22 0.4× 62 1.2× 45 519
Takuro Matsumoto Japan 12 57 0.8× 6 0.1× 175 3.0× 71 1.3× 144 2.8× 68 516
Yoshio Kagitani Japan 10 13 0.2× 8 0.1× 84 1.4× 45 0.8× 21 0.4× 23 369
Katalin Jakab Hungary 10 17 0.2× 6 0.1× 112 1.9× 25 0.5× 182 3.6× 33 409
Shawn Thomas United States 11 18 0.2× 10 0.1× 74 1.3× 70 1.3× 97 1.9× 19 376
Yaming Su United States 8 7 0.1× 19 0.3× 117 2.0× 17 0.3× 143 2.8× 11 306
Sanela Tarabar United States 11 15 0.2× 4 0.1× 76 1.3× 77 1.4× 42 0.8× 14 452

Countries citing papers authored by Morten Bagger

Since Specialization
Citations

This map shows the geographic impact of Morten Bagger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Morten Bagger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Morten Bagger more than expected).

Fields of papers citing papers by Morten Bagger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Morten Bagger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Morten Bagger. The network helps show where Morten Bagger may publish in the future.

Co-authorship network of co-authors of Morten Bagger

This figure shows the co-authorship network connecting the top 25 collaborators of Morten Bagger. A scholar is included among the top collaborators of Morten Bagger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Morten Bagger. Morten Bagger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
DiDonato, Michael, Catherine Simpson, Todd Vo, et al.. (2025). A novel interleukin-10 antibody graft to treat inflammatory bowel disease. Structure. 33(3). 475–488.e7. 1 indexed citations
2.
Ando, Kiyoshi, Laimonas Griškevičius, Takayuki Ikezoe, et al.. (2023). P789: EFFICACY AND SAFETY OF SWITCHING TO IPTACOPAN (IPTA) MONOTHERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATED WITH THE ANTI-C5 MONOCLONAL ANTIBODY (MAB) TESIDOLUMAB (TESI). HemaSphere. 7(S3). e17022e8–e17022e8. 1 indexed citations
3.
Yu, Huixin, Gordon Graham, Olivier J. David, et al.. (2022). Population Pharmacokinetic–B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis. CNS Drugs. 36(3). 283–300. 24 indexed citations
4.
Hauser, Stephen L., Anne H. Cross, Kevin Winthrop, et al.. (2022). Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years. Multiple Sclerosis Journal. 28(10). 1576–1590. 45 indexed citations
5.
Bar‐Or, Amit, Xavier Montalbán, Harald Kropshofer, et al.. (2022). Serum Neurofilament Light Trajectories and Their Relation to Subclinical Radiological Disease Activity in Relapsing Multiple Sclerosis Patients in the APLIOS Trial. Neurology and Therapy. 12(1). 303–317. 10 indexed citations
6.
Jones, Byron, et al.. (2022). Statistical methodology for highly variable compounds: A novel design approach for the ofatumumab Phase 2 bioequivalence study. Pharmaceutical Statistics. 21(6). 1357–1365. 1 indexed citations
7.
Delgado, Silvia, Mitzi Williams, Morten Bagger, et al.. (2021). Comparable Ofatumumab Treatment Outcomes in Patients across Racial/Ethnic Groups in the ASCLEPIOS I/II and APOLITOS studies (4139). Neurology. 96(15_supplement). 2 indexed citations
8.
Luetjens, C. Marc, Morten Bagger, Esther Sutter, et al.. (2021). Effect of ofatumumab on pregnancy, parturition, and lactation in cynomolgus monkeys. Reproductive Toxicology. 108. 28–34. 4 indexed citations
9.
Bagger, Morten, Esther Sutter, Anthony M. DeLise, et al.. (2021). Effect of Ofatumumab on Pregnancy, Parturition and Lactation in Cynomolgus Monkeys (2265). Neurology. 96(15_supplement). 1 indexed citations
10.
Bar‐Or, Amit, Edward Fox, Alexandra Goodyear, et al.. (2020). Onset of B-cell Depletion and Suppression of MRI Activity with Ofatumumab Treatment in Relapsing Multiple Sclerosis: The APLIOS Study (3971). Neurology. 94(15_supplement). 1 indexed citations
11.
Jordan, Stanley C., Klaus Kucher, Morten Bagger, et al.. (2020). Intravenous immunoglobulin significantly reduces exposure of concomitantly administered anti-C5 monoclonal antibody tesidolumab. American Journal of Transplantation. 20(9). 2581–2588. 21 indexed citations
12.
Christensen, Michael, et al.. (2004). Acyclovir prodrug for the intestinal di/tri-peptide transporter PEPT1: comparison of in vivo bioavailability in rats and transport in Caco-2 cells. European Journal of Pharmaceutical Sciences. 23(4-5). 319–325. 33 indexed citations
13.
Bagger, Morten & Erik Bechgaard. (2003). The potential of nasal application for delivery to the central brain—a microdialysis study of fluorescein in rats. European Journal of Pharmaceutical Sciences. 21(2-3). 235–242. 41 indexed citations
14.
Bagger, Morten & Erik Bechgaard. (2003). A microdialysis model to examine nasal drug delivery and olfactory absorption in rats using lidocaine hydrochloride as a model drug. International Journal of Pharmaceutics. 269(2). 311–322. 25 indexed citations
15.
Bagger, Morten, et al.. (2001). Nasal bioavailability of peptide T in rabbits: absorption enhancement by sodium glycocholate and glycofurol. European Journal of Pharmaceutical Sciences. 14(1). 69–74. 29 indexed citations
16.
Bagger, Morten, et al.. (2001). Intranasal bioavailability of buprenorphine in rabbit correlated to sheep and man. International Journal of Pharmaceutics. 217(1-2). 121–126. 18 indexed citations
17.
Bechgaard, Erik, et al.. (1997). High-performance liquid chromatographic analysis of Peptide T in rabbit plasma with on-line column enrichment. Journal of Chromatography B Biomedical Sciences and Applications. 693(1). 237–240. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Poorva Jain Breakdown of academic impact, for papers by Alan I. Mandell Breakdown of academic impact, for papers by Mahmoud Al‐Kofahi Breakdown of academic impact, for papers by Sakae Itoga Breakdown of academic impact, for papers by Takuro Matsumoto Breakdown of academic impact, for papers by Yoshio Kagitani Breakdown of academic impact, for papers by Katalin Jakab Breakdown of academic impact, for papers by Shawn Thomas Breakdown of academic impact, for papers by Yaming Su Breakdown of academic impact, for papers by Sanela Tarabar
Rankless by CCL
2026